In particular, the study of gene expression mechanisms and like potential therapeutic of NR4A2 has been carried out using CRISPR/Cas technology and VAA vectors, especially in the field of oncology, but also in PD, AD and substance use disorders [199,201,212,213,214]. This evidence concerns the gene NR4A2 and Parkinson disease.